Cognition comes of age: comments on the new FDA draft guidance for early Alzheimer’s disease

by John E. Harrison
Published 2018-06-01

Commentary: Composite cognitive and functional measures for early stage Alzheimer's disease trials

by John E. Harrison
Published 2020-01-01

Evaluation of Speech-Based Digital Biomarkers: Review and Recommendations

by Jessica Robin, John E. Harrison, Liam D. Kaufman, Frank Rudzicz, William Simpson, Maria Yancheva
Published 2020-10-01

A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer’s disease

by Niels D. Prins, John E. Harrison, Hui-May Chu, Kelly Blackburn, John J. Alam, Philip Scheltens, for the REVERSE-SD Study Investigators
Published 2021-05-01

Assessing cognition and daily function in early dementia using the cognitive-functional composite: findings from the Catch-Cog study cohort

by Roos J. Jutten, John E. Harrison, Philippe R. Lee Meeuw Kjoe, Silvia Ingala, R. Vreeswijk, R. A. J. van Deelen, Frank Jan de Jong, Esther M. Opmeer, André Aleman, Craig W. Ritchie, Philip Scheltens, Sietske A. M. Sikkes
Published 2019-05-01

The clinical promise of biomarkers of synapse damage or loss in Alzheimer’s disease

by Martí Colom-Cadena, Tara Spires-Jones, Henrik Zetterberg, Kaj Blennow, Anthony Caggiano, Steven T. DeKosky, Howard Fillit, John E. Harrison, Lon S. Schneider, Phillip Scheltens, Willem de Haan, Michael Grundman, Christopher H. van Dyck, Nicholas J. Izzo, Susan M. Catalano, the Synaptic Health Endpoints Working Group
Published 2020-03-01